United States-based Neurocrine Biosciences has signed a research collaboration with United States-based Jnana Therapeutics.
It was reported yesterday that the collaboration is aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system disorders. It will leverage Jnana Therapeutics' proprietary drug discovery platform across the solute carrier family of transporters and Neurocrine's research and development expertise in central nervous system disorders to advance new medicines.
According to the terms of the contract, both firms will work jointly to identify novel compounds, after which time Neurocrine will be responsible for further lead optimisation, and the development and commercialisation of any potential therapies arising from the collaboration.
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease
Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc
Neuraxpharm acquires Provigil and Nuvigil to expand CNS portfolio
Nuvation Bio secures NMPA approval for taletrectinib in China
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities